Last reviewed · How we verify
Zoloft (antidepressant)
Zoloft selectively blocks the reuptake of serotonin in the brain, increasing serotonin availability at synapses.
Zoloft selectively blocks the reuptake of serotonin in the brain, increasing serotonin availability at synapses. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.
At a glance
| Generic name | Zoloft (antidepressant) |
|---|---|
| Also known as | Sertraline |
| Sponsor | Unity Health Toronto |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Zoloft (sertraline) is a selective serotonin reuptake inhibitor (SSRI) that binds to the serotonin transporter protein and prevents the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The mechanism is thought to underlie its efficacy in treating depression and anxiety disorders.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Post-traumatic stress disorder
- Social anxiety disorder
- Generalized anxiety disorder
- Premenstrual dysphoric disorder
Common side effects
- Sexual dysfunction
- Nausea
- Headache
- Diarrhea
- Insomnia
- Somnolence
- Tremor
- Dry mouth
Key clinical trials
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan (NA)
- ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression (PHASE2)
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
- The Friendship Bench Plus Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoloft (antidepressant) CI brief — competitive landscape report
- Zoloft (antidepressant) updates RSS · CI watch RSS
- Unity Health Toronto portfolio CI